Abstract
IntroductionInfliximab (IFX), a monoclonal chimeric antibody against tumour necrosis factor (TNF) α, is effective for induction and maintenance of remission in moderate to severe Crohn's disease. Discontinuation of IFX maintenance...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have